Trial Profile
A Phase II Study of PNT2258 in Patients With Richter's Transformation (RT)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Jun 2023
Price :
$35
*
At a glance
- Drugs Rosomidnar (Primary)
- Indications Richter's syndrome
- Focus Registrational; Therapeutic Use
- Acronyms Brighton
- Sponsors Sierra Oncology
- 27 Jul 2020 This trial has been completed in United Kingdom, according to European Clinical Trials Database record.
- 09 Jan 2017 According to a Sierra Oncology media release, this trial was originally conducted by ProNAi Therapeutics, Inc. but later on this company's name changed to Sierra Oncology.
- 06 Jun 2016 Status changed from recruiting to suspended, according to a ProNAi Therapeutics media release.